Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 4/20 | 0.49 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | CHRNG | P07510 | 3/20 | 0.49 |
| ▸ | CHRND | Q07001 | 3/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 3/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855229 | 0.85 | CHRNA1 (0.48) | CHRNA1CHRNB1CHRNB2SLC6A2CHRNB4 | |
| SCHEMBL3995603 | 0.77 | TAAR1 (0.43) | CHRNA1CHRNB1CHRNB2SLC6A2CHRNB4 | |
| SCHEMBL873359 | 0.77 | CHRNB2 (0.41) | CHRNA1CHRNB1CHRNB2SLC6A2CHRNB4 | |
| SCHEMBL241074 | 0.75 | CHRNA1 (0.47) | CHRNA1CHRNB1CHRNB2SLC6A2CHRNB4 | |
| SCHEMBL3647973 | 0.74 | CHRNA1 (0.48) | CHRNA1CHRNB1CHRNB2SLC6A2CHRNB4 | |
| SCHEMBL8551681 | 0.73 | MAOB (0.43) | CHRNA1CHRNB1CHRNB2SLC6A2CHRNB4 | |
| SCHEMBL3327547 | 0.73 | CHRNA1 (0.47) | CHRNA1CHRNB1CHRNB2SLC6A2CHRNB4 | |
| SCHEMBL16097817 | 0.72 | ALOX5 (0.49) | CHRNA1CHRNB1CHRNB2SLC6A2CHRNB4 | |
| SCHEMBL4882640 | 0.72 | CHRNB2 (0.54) | CHRNA1CHRNB1CHRNB2SLC6A2CHRNB4 | |
| SCHEMBL8551682 | 0.71 | CHRNA1 (0.38) | CHRNA1CHRNB1CHRNB2SLC6A2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206219-B2 | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-20120258941-A1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR TREATING DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-11 | — | — | US | disclosed |
| EP-2456780-A2 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR TREATING DISEASES | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011009534-A2 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR TREATING DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | WO | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2008077646-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | NR5A1, CYP19A1, GPER1 | CHRNA1 584/4885CHRNB1 1111/4885CHRNB2 3527/4885 |
| US-20120258941-A1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR TREATING DISEASES | CYP19A1, SHBG, HSD17B11 | CHRNA1 1198/4885CHRNB1 999/4885CHRNB2 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.